Sichuan Kelun Pharmaceutical Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
20,127
- Stock Symbol
-
002422
- Investments
-
7
- Share Price
-
$6.34
- (As of Wednesday Closing)
Sichuan Kelun Pharmaceutical General Information
Description
Sichuan Kelun Pharmaceutical Co Ltd is a China-based pharmaceutical company focused on the manufacturing of infusion products, antibiotics, and various medical devices. The company operates its businesses through three segments. The Twinings segment focuses on producing pharmaceutical intermediates. The Botai segment is dedicated to the research, development, manufacturing, and commercialization of medicines. The Other Business segment covers activities such as the development and production of large-volume injections, along with the research, manufacturing, and sales of additional pharmaceutical products and related businesses.
Contact Information
Website
www.kelun.comCorporate Office
- Number 36 West Baihua Road
- Chengdu, Sichuan 610071
- China
Corporate Office
- Number 36 West Baihua Road
- Chengdu, Sichuan 610071
- China
Sichuan Kelun Pharmaceutical Stock Performance
As of 18-Nov-2026, Sichuan Kelun Pharmaceutical’s stock price is $6.34. Its current market cap is $10.1B with 1.59B shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.34 | $6.35 | $4.02 - $7.79 | $10.1B | 1.59B | 19.5M | $0.18 |
Sichuan Kelun Pharmaceutical Financials Summary
As of 30-Sep-2026, Sichuan Kelun Pharmaceutical has a trailing 12-month revenue of $2.66B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,712,395 | 6,875,151 | 6,755,256 | 6,653,831 |
| Revenue | 2,662,087 | 2,574,342 | 3,039,863 | 3,032,409 |
| EBITDA | 399,152 | 531,915 | 787,001 | 718,351 |
| Net Income | 285,563 | 236,665 | 409,157 | 347,160 |
| Total Assets | 6,419,177 | 5,693,373 | 5,111,746 | 5,142,751 |
| Total Debt | 560,323 | 500,864 | 576,355 | 1,007,177 |
Sichuan Kelun Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sichuan Kelun Pharmaceutical Patents
Sichuan Kelun Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026103427-A1 | Double butterfly valve-based sterile medicine transfer system and sterile medicine transfer method | Pending | 15-Nov-2024 | ||
| WO-2026103486-A1 | Method for determining contents of linoleic acid and α-linolenic acid in fat emulsion injection | Pending | 12-Nov-2024 | ||
| WO-2026086694-A1 | Pediatric compound amino acid injection and preparation method therefor | Pending | 23-Oct-2024 | ||
| WO-2025020316-A1 | Cavity welding mold | Inactive | 27-Jul-2023 | ||
| WO-2025020379-A1 | Multi-chamber sterilization and water removal device for infusion bags | Inactive | 27-Jul-2023 | A61L2/26 |
Sichuan Kelun Pharmaceutical Signals
Sichuan Kelun Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sichuan Kelun Pharmaceutical Investments & Acquisitions (7)
Sichuan Kelun Pharmaceutical’s most recent deal was a Merger/Acquisition with Jiangsu Huashitong for . The deal was made on 15-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Jiangsu Huashitong | 15-Jul-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Kelun Biotech | 29-Dec-2022 | Later Stage VC | Drug Discovery | ||
| Industrial Cloud Manufacturing | 08-Apr-2022 | Later Stage VC | Business/Productivity Software | ||
| Cisen | 28-Jul-2021 | Secondary Transaction - Private | Pharmaceuticals | ||
| Klus Pharma | 28-Oct-2016 | Merger/Acquisition | Drug Discovery |
Sichuan Kelun Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
30.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Sichuan Kelun Pharmaceutical Exits (1)
Sichuan Kelun Pharmaceutical’s most recent exit was on 29-Dec-2022 from Kelun Biotech. The exit was categorized as with 9 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kelun Biotech | 29-Dec-2022 | Completed |
|
Sichuan Kelun Pharmaceutical Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kelun Biotech | Chengdu, China | 2016 | |
| Jiangsu Huashitong | Taizhou, China | 2016 | |
| Klus Pharma | Princeton, NJ | 2014 |
Sichuan Kelun Pharmaceutical FAQs
-
When was Sichuan Kelun Pharmaceutical founded?
Sichuan Kelun Pharmaceutical was founded in 1996.
-
Where is Sichuan Kelun Pharmaceutical headquartered?
Sichuan Kelun Pharmaceutical is headquartered in Chengdu, China.
-
What is the size of Sichuan Kelun Pharmaceutical?
Sichuan Kelun Pharmaceutical has 20,127 total employees.
-
What industry is Sichuan Kelun Pharmaceutical in?
Sichuan Kelun Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Sichuan Kelun Pharmaceutical a private or public company?
Sichuan Kelun Pharmaceutical is a Public company.
-
What is Sichuan Kelun Pharmaceutical’s stock symbol?
The ticker symbol for Sichuan Kelun Pharmaceutical is 002422.
-
What is the current stock price of Sichuan Kelun Pharmaceutical?
As of 18-Nov-2026 the stock price of Sichuan Kelun Pharmaceutical is $6.34.
-
What is the current market cap of Sichuan Kelun Pharmaceutical?
The current market capitalization of Sichuan Kelun Pharmaceutical is $10.1B.
-
What is Sichuan Kelun Pharmaceutical’s current revenue?
The trailing twelve month revenue for Sichuan Kelun Pharmaceutical is $2.66B.
-
What is Sichuan Kelun Pharmaceutical’s annual earnings per share (EPS)?
Sichuan Kelun Pharmaceutical’s EPS for 12 months was $0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process